On average, across all breast cancer samples analyzed by KSTAR in this study, roughly 30% of HER2-negative patients might have basal levels of HER2-activity, suggesting the possibility of a therapeutic avenue not normally offered HER2-negative patients. Here, ERBB2 is linked to breast cancer.